<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39405450</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Remdesivir Effectiveness in Reducing the Risk of 30-day Readmission in Vulnerable Patients Hospitalized for COVID-19: A Retrospective US Cohort Study Using Propensity Scores.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ciae511</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciae511</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Reducing hospital readmission offer potential benefits for patients, providers, payers, and policymakers to improve quality of healthcare, reduce cost, and improve patient experience. We investigated effectiveness of remdesivir in reducing 30-day COVID-19-related readmission during the Omicron era, including older adults and those with underlying immunocompromising conditions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective study utilized the US PINC AI Healthcare Database to identify adult patients discharged alive from an index COVID-19 hospitalization between December 01, 2021 and February 29, 2024. Odds of 30-day COVID-19-related readmission to the same hospital were compared between patients who received remdesivir vs those not, after balancing characteristics of two groups using inverse probability of treatment weighting (IPTW). Analyses were stratified by maximum supplemental oxygen requirement during index hospitalization.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 326,033 patients hospitalized for COVID-19 during study period, 210,586 patients met the eligibility criteria. Of these, 109,551 (52%) patients were treated with remdesivir. After IPTW, lower odds of 30-day COVID-19-related readmission were observed in patients who received remdesivir vs those who did not, in the overall population (3.3% vs 4.2%, respectively; odds ratio [95% confidence interval]: 0.78 [0.75-0.80]), elderly population (3.7% vs 4.7%, respectively; 0.78 [0.75-0.81]), and those with underlying immunocompromising conditions (5.3% vs 6.2%, respectively; 0.86 [0.80-0.92]). These results were consistent irrespective of supplemental oxygen requirements.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Treating patients hospitalized for COVID-19 with remdesivir was associated with a significantly lower likelihood of 30-day COVID-19-related readmission across all patients discharged alive from the initial COVID-19 hospitalization, including older adults and those with underlying immunocompromising conditions.</AbstractText><CopyrightInformation>Â© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mozaffari</LastName><ForeName>Essy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandak</LastName><ForeName>Aastha</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5653-435X</Identifier><AffiliationInfo><Affiliation>Certara, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottlieb</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials><Identifier Source="ORCID">0000-0001-8376-8709</Identifier><AffiliationInfo><Affiliation>Baylor University Medical Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Baylor Scott &amp; White Heart and Vascular Hospital, Dallas, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Baylor Scott &amp; White The Heart Hospital, Plano, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Baylor Scott &amp; White Research Institute, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalil</LastName><ForeName>Andre C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>University of Nebraska Medical Center, Omaha, Nebraska, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Heng</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7536-9089</Identifier><AffiliationInfo><Affiliation>Certara, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oppelt</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-2865-9854</Identifier><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8534-2012</Identifier><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chima-Melton</LastName><ForeName>Chidinma</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0730-9871</Identifier><AffiliationInfo><Affiliation>Tele-ICU Inc, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pipeline Health System, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Alpesh N</ForeName><Initials>AN</Initials><Identifier Source="ORCID">0000-0002-9790-0245</Identifier><AffiliationInfo><Affiliation>University of California Irvine, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">United States</Keyword><Keyword MajorTopicYN="N">data science</Keyword><Keyword MajorTopicYN="N">inverse probability of treatment weighting</Keyword><Keyword MajorTopicYN="N">propensity scores</Keyword><Keyword MajorTopicYN="N">readmission</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>15</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39405450</ArticleId><ArticleId IdType="doi">10.1093/cid/ciae511</ArticleId><ArticleId IdType="pii">7823125</ArticleId></ArticleIdList></PubmedData></PubmedArticle>